Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.

Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE.

Clin Immunol. 2018 Jul 17;195:28-35. doi: 10.1016/j.clim.2018.06.008. [Epub ahead of print]

PMID:
30025819
2.

Eccentric cycling emphasising a low cardiopulmonary demand increases leg strength equivalent to workload matched concentric cycling in middle age sedentary males.

Lewis MC, Peoples GE, Groeller H, Brown MA.

J Sci Med Sport. 2018 May 15. pii: S1440-2440(18)30143-9. doi: 10.1016/j.jsams.2018.05.009. [Epub ahead of print]

PMID:
29789262
3.

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.

Herbert GS, Vreeland TJ, Clifton GT, Greene JM, Jackson DO, Hardin MO, Hale DF, Berry JS, Nichol P, Yin S, Yu X, Wagner TE, Peoples GE.

Vaccine. 2018 May 31;36(23):3247-3253. doi: 10.1016/j.vaccine.2018.04.078. Epub 2018 May 1.

PMID:
29724512
4.

Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.

Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA.

Clin Immunol. 2018 Jul;192:6-13. doi: 10.1016/j.clim.2018.03.010. Epub 2018 Mar 21.

PMID:
29574039
5.

Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.

Hardin MO, Vreeland TJ, Clifton GT, Hale DF, Herbert GS, Greene JM, Jackson DO, Berry JE, Nichols P, Yin S, Yu X, Wagner TE, Peoples GE.

Immunotherapy. 2018 Apr;10(5):373-382. doi: 10.2217/imt-2017-0114.

PMID:
29473470
6.

A vascular mechanism to explain thermally mediated variations in deep-body cooling rates during the immersion of profoundly hyperthermic individuals.

Caldwell JN, van den Heuvel AMJ, Kerry P, Clark MJ, Peoples GE, Taylor NAS.

Exp Physiol. 2018 Apr 1;103(4):512-522. doi: 10.1113/EP086760. Epub 2018 Feb 28.

PMID:
29345019
7.

Routine Pre-Treatment MRI for Breast Cancer in a Single-Payer Medical Center: Effects on Surgical Choices, Timing and Outcomes.

Vreeland TJ, Berry Iv JS, Schneble E, Jackson DO, Herbert GS, Hale DF, Martin JM, Flores M, Pattyn AR, Hata K, Clifton GT, Kirkpatrick AD, Peoples GE.

J Cancer. 2017 Jul 23;8(13):2442-2448. doi: 10.7150/jca.16738. eCollection 2017.

8.

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA.

Cancer Res. 2017 Oct 1;77(19):5374-5383. doi: 10.1158/0008-5472.CAN-16-2774. Epub 2017 Aug 17.

PMID:
28819024
9.

Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development.

Berry JS, Vreeland TJ, Hale DF, Jackson DO, Trappey AF, Greene JM, Hardin MO, Herbert GS, Clifton GT, Peoples GE.

J Cancer. 2017 May 11;8(7):1255-1262. doi: 10.7150/jca.16450. eCollection 2017.

10.

Algal supplementation of vegetarian eating patterns improves plasma and serum docosahexaenoic acid concentrations and omega-3 indices: a systematic literature review.

Craddock JC, Neale EP, Probst YC, Peoples GE.

J Hum Nutr Diet. 2017 Dec;30(6):693-699. doi: 10.1111/jhn.12474. Epub 2017 Apr 17. Review.

PMID:
28417511
11.

DHA-rich Fish Oil Increases the Omega-3 Index and Lowers the Oxygen Cost of Physiologically Stressful Cycling in Trained Individuals.

Hingley L, Macartney MJ, Brown MA, McLennan PL, Peoples GE.

Int J Sport Nutr Exerc Metab. 2017 Aug;27(4):335-343. doi: 10.1123/ijsnem.2016-0150. Epub 2017 Mar 24.

PMID:
28338369
12.

Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.

Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA.

Ann Surg Oncol. 2017 Aug;24(8):2161-2167. doi: 10.1245/s10434-017-5844-0. Epub 2017 Mar 17.

13.

Dietary fish oil delays hypoxic skeletal muscle fatigue and enhances caffeine-stimulated contractile recovery in the rat in vivo hindlimb.

Peoples GE, McLennan PL.

Appl Physiol Nutr Metab. 2017 Jun;42(6):613-620. doi: 10.1139/apnm-2016-0501. Epub 2017 Jan 26.

PMID:
28177707
14.

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.

Jackson DO, Byrd K, Vreeland TJ, Hale DF, Herbert GS, Greene JM, Schneble EJ, Berry JS, Trappey AF, Clifton GT, Hardin MO, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwell GL, Peoples GE.

Oncotarget. 2017 Feb 28;8(9):15912-15923. doi: 10.18632/oncotarget.13305.

15.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE.

Oncotarget. 2016 Oct 4;7(40):66192-66201. doi: 10.18632/oncotarget.11751.

16.

Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.

Berry J, Vreeland T, Trappey A, Hale D, Peace K, Tyler J, Walker A, Brown R, Herbert G, Yi F, Jackson D, Clifton G, Peoples GE.

Expert Rev Clin Immunol. 2017 Mar;13(3):235-245. doi: 10.1080/1744666X.2016.1226132. Epub 2016 Aug 30. Review.

PMID:
27552944
17.

Predictive Validity of a Thigh-Worn Accelerometer METs Algorithm in 5- to 12-Year-old Children.

van Loo CM, Okely AD, Batterham M, Hinkley T, Ekelund U, Brage S, Reilly JJ, Peoples GE, Jones R, Janssen X, Cliff DP.

J Phys Act Health. 2016 Jun;13(6 Suppl 1):S78-83. doi: 10.1123/jpah.2015-0721.

PMID:
27392386
18.

Energy Cost of Physical Activities and Sedentary Behaviors in Young Children.

Großek A, van Loo C, Peoples GE, Hagenbuchner M, Jones R, Cliff DP.

J Phys Act Health. 2016 Jun;13(6 Suppl 1):S7-S10. doi: 10.1123/jpah.2015-0720.

PMID:
27392383
19.

Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.

Vreeland TJ, Clifton GT, Herbert GS, Hale DF, Jackson DO, Berry JS, Peoples GE.

Expert Rev Clin Immunol. 2016 Dec;12(12):1347-1357. Epub 2016 Jun 28. Review.

PMID:
27323245
20.

Load carriage, human performance, and employment standards.

Taylor NA, Peoples GE, Petersen SR.

Appl Physiol Nutr Metab. 2016 Jun;41(6 Suppl 2):S131-47. doi: 10.1139/apnm-2015-0486. Review.

21.

Validation of the SenseWear Mini activity monitor in 5-12-year-old children.

van Loo CM, Okely AD, Batterham MJ, Hinkley T, Ekelund U, Brage S, Reilly JJ, Peoples GE, Jones RA, Janssen X, Cliff DP.

J Sci Med Sport. 2017 Jan;20(1):55-59. doi: 10.1016/j.jsams.2016.04.010. Epub 2016 May 6.

PMID:
27256787
22.

Arming the Immune System Through Vaccination to Prevent Cancer Recurrence.

Hale DF, Vreeland TJ, Peoples GE.

Am Soc Clin Oncol Educ Book. 2016;35:e159-67. doi: 10.14694/EDBK_158946. Review.

23.

Clinical Development of the E75 Vaccine in Breast Cancer.

Clifton GT, Gall V, Peoples GE, Mittendorf EA.

Breast Care (Basel). 2016 Apr;11(2):116-21. doi: 10.1159/000446097. Epub 2016 Apr 26. Review.

24.

Injecting Hope--A Review of Breast Cancer Vaccines.

Mittendorf EA, Peoples GE.

Oncology (Williston Park). 2016 May;30(5):475-81, 485. Review.

25.

Peptide-Based Cancer Vaccine Strategies and Clinical Results.

Schneble E, Clifton GT, Hale DF, Peoples GE.

Methods Mol Biol. 2016;1403:797-817. doi: 10.1007/978-1-4939-3387-7_46. Review.

PMID:
27076168
26.

The development and use of the E75 (HER2 369-377) peptide vaccine.

Clifton GT, Peoples GE, Mittendorf EA.

Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054. Epub 2016 Apr 5.

27.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE.

Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30.

28.

A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.

Greene JM, Schneble EJ, Jackson DO, Hale DF, Vreeland TJ, Flores M, Martin J, Herbert GS, Hardin MO, Yu X, Wagner TE, Peoples GE.

Cancer Immunol Immunother. 2016 Apr;65(4):383-92. doi: 10.1007/s00262-016-1809-6. Epub 2016 Feb 19.

PMID:
26894495
29.

Balancing ballistic protection against physiological strain: evidence from laboratory and field trials.

Taylor NA, Burdon CA, van den Heuvel AM, Fogarty AL, Notley SR, Hunt AP, Billing DC, Drain JR, Silk AJ, Patterson MJ, Peoples GE.

Appl Physiol Nutr Metab. 2016 Feb;41(2):117-24. doi: 10.1139/apnm-2015-0386. Epub 2015 Oct 16.

PMID:
26771198
30.

The effects of thoracic load carriage on maximal ambulatory work tolerance and acceptable work durations.

Peoples GE, Lee DS, Notley SR, Taylor NA.

Eur J Appl Physiol. 2016 Mar;116(3):635-46. doi: 10.1007/s00421-015-3323-5. Epub 2016 Jan 6.

PMID:
26739503
31.

Analysis of Clinical and Pathologic Factors of Pure, Flat Epithelial Atypia on Core Needle Biopsy to Aid in the Decision of Excision or Observation.

Berry JS, Trappey AF, Vreeland TJ, Pattyn AR, Clifton GT, Berry EA, Schneble EJ, Kirkpatrick AD, Saenger JS, Peoples GE.

J Cancer. 2016 Jan 1;7(1):1-6. doi: 10.7150/jca.12781. eCollection 2016.

32.

Vegetarian and Omnivorous Nutrition - Comparing Physical Performance.

Craddock JC, Probst YC, Peoples GE.

Int J Sport Nutr Exerc Metab. 2016 Jun;26(3):212-20. doi: 10.1123/ijsnem.2015-0231. Epub 2015 Nov 16. Review.

PMID:
26568522
33.

Adjuvant HER2/neu peptide cancer vaccines in breast cancer.

Clifton GT, Mittendorf EA, Peoples GE.

Immunotherapy. 2015;7(11):1159-68. doi: 10.2217/imt.15.81. Epub 2015 Nov 16. Review.

PMID:
26567563
34.

Critical issues in cancer vaccine trial design.

Clifton GT, Kohrt HE, Peoples GE.

Vaccine. 2015 Dec 16;33(51):7386-7392. doi: 10.1016/j.vaccine.2015.09.019. Epub 2015 Sep 19. Review.

PMID:
26392010
35.
36.

The utility of heart rate and minute ventilation as predictors of whole-body metabolic rate during occupational simulations involving load carriage.

Notley SR, Peoples GE, Taylor NA.

Ergonomics. 2015;58(10):1671-81. doi: 10.1080/00140139.2015.1026406. Epub 2015 Apr 15.

PMID:
25746518
37.

Novel dendritic cell-based vaccination in late stage melanoma.

Schneble EJ, Yu X, Wagner TE, Peoples GE.

Hum Vaccin Immunother. 2014;10(11):3132-8. doi: 10.4161/hv.29110. Review.

38.

Intrinsic heart rate recovery after dynamic exercise is improved with an increased omega-3 index in healthy males.

Macartney MJ, Hingley L, Brown MA, Peoples GE, McLennan PL.

Br J Nutr. 2014 Dec 28;112(12):1984-92. doi: 10.1017/S0007114514003146. Epub 2014 Oct 30.

PMID:
25355484
39.

Prediction of activity type in preschool children using machine learning techniques.

Hagenbuchner M, Cliff DP, Trost SG, Van Tuc N, Peoples GE.

J Sci Med Sport. 2015 Jul;18(4):426-31. doi: 10.1016/j.jsams.2014.06.003. Epub 2014 Jun 24.

PMID:
25088983
40.

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.

Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE.

Ann Oncol. 2014 Sep;25(9):1735-42. doi: 10.1093/annonc/mdu211. Epub 2014 Jun 6.

41.

The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.

Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE.

Immunotherapy. 2014;6(5):519-31. doi: 10.2217/imt.14.22. Review.

PMID:
24896623
42.

Time-dependent estimates of recurrence and survival in colon cancer: clinical decision support system tool development for adjuvant therapy and oncological outcome assessment.

Steele SR, Bilchik A, Johnson EK, Nissan A, Peoples GE, Eberhardt JS, Kalina P, Petersen B, Brücher B, Protic M, Avital I, Stojadinovic A.

Am Surg. 2014 May;80(5):441-53.

PMID:
24887722
43.

Future directions for the early detection of recurrent breast cancer.

Schneble EJ, Graham LJ, Shupe MP, Flynt FL, Banks KP, Kirkpatrick AD, Nissan A, Henry L, Stojadinovic A, Shumway NM, Avital I, Peoples GE, Setlik RF.

J Cancer. 2014 Mar 16;5(4):291-300. doi: 10.7150/jca.8017. eCollection 2014. Review.

44.

Current approaches and challenges in early detection of breast cancer recurrence.

Schneble EJ, Graham LJ, Shupe MP, Flynt FL, Banks KP, Kirkpatrick AD, Nissan A, Henry L, Stojadinovic A, Shumway NM, Avital I, Peoples GE, Setlik RF.

J Cancer. 2014 Mar 16;5(4):281-90. doi: 10.7150/jca.8016. eCollection 2014. Review.

45.

Special issue on current challenges and future directions in monitoring recurrence after treatment of primary cancer.

Stojadinovic A, Avital I, Peoples GE, Steele S.

J Cancer. 2014 Mar 15;5(4):260-1. doi: 10.7150/jca.9070. eCollection 2014. No abstract available.

46.

Invariant chain-peptide fusion vaccine using HER-2/neu.

Perez SA, Peoples GE, Papamichail M, Baxevanis CN.

Methods Mol Biol. 2014;1139:321-36. doi: 10.1007/978-1-4939-0345-0_26.

PMID:
24619690
47.

Revisiting ventilatory and cardiovascular predictions of whole-body metabolic rate.

Notley SR, Fullagar HH, Lee DS, Matsuda-Nakamura M, Peoples GE, Taylor NA.

J Occup Environ Med. 2014 Feb;56(2):214-23. doi: 10.1097/JOM.0000000000000086.

PMID:
24451619
48.

Future directions for monitoring treatment responses in breast cancer.

Shupe MP, Graham LJ, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, Stojadinovic A, Peoples GE, Shumway NM.

J Cancer. 2014 Jan 5;5(1):69-78. doi: 10.7150/jca.7048. Review.

49.

Current approaches and challenges in monitoring treatment responses in breast cancer.

Graham LJ, Shupe MP, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, Gallagher C, Nissan A, Henry L, Stojadinovic A, Peoples GE, Shumway NM.

J Cancer. 2014 Jan 5;5(1):58-68. doi: 10.7150/jca.7047. Review.

50.

Special issue on current challenges and future directions in monitoring responses after treatment of primary cancer.

Stojadinovic A, Avital I, Wallace TJ, Peoples GE, Steele S.

J Cancer. 2014 Jan 1;5(1):1-2. doi: 10.7150/jca.7609. eCollection 2014. No abstract available.

Supplemental Content

Loading ...
Support Center